Medivir granted US combination patent for fostrox plus lenvatinib, protection extended by almost three years to January 2044
Medivir granted US combination patent for fostrox plus lenvatinib, protection extended by almost three years to January 2044
Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments in areas of high unmet medical need, announces today that the United States Patent and Trademark Office (USPTO) has granted the company's patent US12788771, covering claims for the combination of fostroxacitabine bralpamide (fostrox) with lenvatinib for the treatment of hepatocellular carcinoma (HCC) and cancer metastases to the liver. The grant follows the Notice of Allowance announced on 20 July 2026.
In connection with the grant, the USPTO has determined a Patent Term Adjustment (PTA) of 1,001 days, which compensates for administrative delays during the examination of the patent application. As a result, the fostrox plus lenvatinib combination patent provides protection and market exclusivity in the US until at least January 2044, compared with April 2041 as previously communicated, an extension of almost three years. The US patent adds to the previously granted patents for the combination in the EU, Japan, Australia and Canada.
“The grant of the US patent for the fostrox plus lenvatinib combination is, together with the fostrox composition of matter patent, an important part of our strategy to protect clinically relevant combinations with fostrox in liver cancer. The Patent Term Adjustment of 1,001 days, extending protection to January 2044, significantly strengthens the long-term commercial value of fostrox in the US, the world’s largest pharmaceutical market, at a time when the combination is being evaluated in the randomised phase 2 study FLEX-HCC”, says Jens Lindberg, CEO, Medivir.
For additional information, please contact:
Jens Lindberg, CEO, Medivir AB
Telephone: +46 725 311117
E-mail: jens.lindberg@medivir.com